Adicet Bio
ACET
86 hedge funds and large institutions have $77.4M invested in Adicet Bio in 2024 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 28 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 26
0.85% less ownership
Funds ownership: 5.72% → 4.87% (-0.85%)
10% less funds holding
Funds holding: 96 → 86 (-10)
36% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 28
56% less capital invested
Capital invested by funds: $177M → $77.4M (-$99.2M)
84% less call options, than puts
Call options by funds: $7K | Put options by funds: $44K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$4.24M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.03M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.22M |
| 4 |
D.E. Shaw & Co
New York
|
+$854K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$784K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$14.5M |
| 2 |
RI
RTW Investments
New York
|
-$5.16M |
| 3 |
Morgan Stanley
New York
|
-$4.94M |
| 4 |
BlackRock
New York
|
-$3.95M |
| 5 |
CC
Commodore Capital
New York
|
-$3.23M |
ACET Hedge Fund Activity: Q2 2024 in Review
86 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q2 2024, worth a combined $77.4M — down 56% from $177M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ACET and 18 opened new positions — a net loss of 10 holders — while 26 trimmed existing stakes and 28 added.
The largest buyer was Aquilo Capital Management, opening a new position worth an estimated $4.24M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $14.5M sold.
- 86 institutional investors held Adicet Bio (ACET) as of Q2 2024, down from 96 in Q1 2024.
- Funds reported $77.4M of Adicet Bio stock for Q2 2024, down 56% quarter-over-quarter.
- 18 funds opened new Adicet Bio positions in Q2 2024 and 28 closed out, a net change of -10 holders.
- The largest Adicet Bio buyer in Q2 2024 was Aquilo Capital Management, an estimated $4.24M added.
- The largest Adicet Bio seller in Q2 2024 was Balyasny Asset Management, an estimated $14.5M sold.
Based on aggregated 13F filings for Q2 2024.